US Food & Drug Administration (USFDA) has successfully completed surveillance inspection at Granules India’s Jeedimetla facility located at Hyderabad, Telangana, India from June 19, 2023 to June 23, 2023 with zero (0) 483 observations. Jeedimetla facility manufactures Active Pharmaceutical Ingredients (API) and Pharmaceutical Formulation Intermediates (PFIs).
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
